Loading...

IRWD IRONWOOD PHARMACEUTICALS INC Capital Structure Changes 8-K Filing

RNWD

RWD

IRONWOOD PHARMACEUTICALS INC

(IRWD)

2024 8-K

Show Summary

Summary

Compliance Regained

Earnings Releases

Dismissal of Independent Re...

Notice of Delisting

Financial Statements

Financial Statements

Strategic Alternatives

Earnings Update

Workforce Reduction

Management Change

Management Change

Earnings Update

Credit Agreement Update

Financial Update

Annual Meeting Voting Results

Appointment, Repayment of C...

Financial Update

Earnings Reports

Press Release and Corporate...

Earnings Reports

Earnings Reports

Completion of Acquisition

Annual Meeting Approval

Acquisition Agreement

Earnings Reports

Departure of Directors or C...

Financial Update

Earnings Reports

External Links:

Ironwood Pharmaceuticals amended its credit agreement to increase its revolving credit facility from $500 million to $550 million and extended its maturity date to December 31, 2028, while also adjusting leverage ratios. Additionally, the company decided not to acquire an exclusive license for CNP-104, terminating its agreement with COUR Pharmaceutical.

AI Assistant

IRONWOOD PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.